BCM
PASG icon

BML Capital Management’s Passage Bio PASG Stock Holding History

BML Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-102,938
Closed -$1.35M – 36
2023
Q3 		$1.35M Hold
102,938
– – 1.24% 13
2023
Q2 		$1.94M Buy
102,938
+86,065
+510% +$1.7M 1.74% 14
2023
Q1 		$323K Hold
16,873
– – 0.28% 29
2022
Q4 		$466K Buy
+16,873
New +$426K 0.44% 22

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BML Capital Management's PASG Position: Q4 2023 in Review

BML Capital Management sold out of Passage Bio (PASG) in Q4 2023, closing a stake of 102,938 shares — an estimated $1.35M sold.

BML Capital Management first reported a position in PASG in Q4 2022 and held it in 4 quarters. The position peaked at $1.94M in Q2 2023. 50 funds tracked by Wall St. Rank hold PASG as of Q4 2023.

  • BML Capital Management reported no remaining Passage Bio position as of Q4 2023 after selling out during the quarter.
  • BML Capital Management sold 102,938 Passage Bio shares in Q4 2023, an estimated $1.35M.
  • BML Capital Management first reported a position in Passage Bio in Q4 2022 and held it in 4 quarters.
  • BML Capital Management's Passage Bio position peaked at $1.94M in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Passage Bio as of Q4 2023.

Based on BML Capital Management's 13F filing for Q4 2023, filed 30 Jan 2024.